drugset / Trial / NCT04957719

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719

Phase 3 Enrolling by invitation 25000 enrolled Viatris Innovation GmbH
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.

Timeline

Start
2021-08-14
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Selatogrel Small molecule 16 mg Subcutaneous